<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to evaluation of cholestasis in neonates and young infants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to evaluation of cholestasis in neonates and young infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to evaluation of cholestasis in neonates and young infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amit A Shah, MD, MSHP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathleen M Loomes, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neonatal cholestasis is generally defined as conjugated hyperbilirubinemia that occurs in the newborn period or shortly thereafter. Cholestasis results from diminished bile formation and/or excretion, which can be caused by a number of disorders. Neonatal cholestasis lasting more than two weeks affects approximately 1 in 2500 births (excluding infants with intestinal failure-associated liver disease), but estimates vary depending on the definition used to define cholestasis [<a href="#rid1">1,2</a>].</p><p>This topic review provides a diagnostic approach to patients with neonatal cholestasis. Related material can be found in the following topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholestasis</strong> – Cholestasis is defined as an impairment in the excretion of bile, which can be caused by defects in intrahepatic production of bile, transmembrane transport of bile, or mechanical obstruction to bile flow. The biochemical features of cholestasis reflect the retention of components of bile in the serum (eg, bilirubin, bile acids, and/or cholesterol). The pattern and severity of each of these abnormalities vary with the underlying disorder. Elevated conjugated bilirubin is the predominant characteristic in most of the causes of neonatal cholestasis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjugated hyperbilirubinemia</strong> – In a young infant, a threshold for initiating a clinical evaluation for cholestatic liver disease is conjugated or direct bilirubin &gt;1.0 mg/dL (17.1 micromol/L) [<a href="#rid3">3</a>]. During the neonatal period, milder elevation of conjugated bilirubin is abnormal and warrants close follow-up. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Laboratory studies'</a>.)</p><p></p><p class="bulletIndent1">The threshold is somewhat higher, usually a serum direct bilirubin greater than 2.0 mg/dL (34.2 micromol/L), for defining clinically significant hyperbilirubinemia in infants with intestinal failure-associated liver disease (also known as parenteral nutrition-associated liver disease). (See  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1">The terms "conjugated bilirubin" and "direct bilirubin" are often used interchangeably because conjugated bilirubin can be estimated by the "direct" reaction with a diazo reagent (van den Bergh reaction). However, direct-reacting bilirubin includes both the conjugated bilirubin and the delta fraction, which represents bilirubin covalently bound to albumin [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3573.html" rel="external">"Overview of liver biochemical tests", section on 'Measurement of serum bilirubin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal cholestasis</strong> – The term "neonatal cholestasis" is often used to refer to cholestatic liver disease that is present at birth and/or develops within the first few months of life, rather than referring strictly to the neonatal period (the first 28 days of life). In clinical practice, these disorders usually become apparent within the first two months of life, which is the critical period for identifying infants with biliary atresia  (<a class="graphic graphic_table graphicRef64995" href="/z/d/graphic/64995.html" rel="external">table 1</a>). However, similar diagnostic considerations apply for infants whose cholestasis is identified after two to three months of age. Although the cholestasis caused by these disorders is persistent, infants should be evaluated as soon as the conjugated hyperbilirubinemia is identified to avoid delay in diagnosis.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2885052489"><span class="h2">Indications for evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jaundice</strong> – Any infant noted to be jaundiced at the two-week well-child visit should be evaluated for cholestasis (ie, conjugated hyperbilirubinemia) [<a href="#rid3">3</a>]. This is because physiologic jaundice (characterized by unconjugated hyperbilirubinemia) resolves by 14 days of age in at least 85 percent of infants [<a href="#rid5">5,6</a>]. Although most infants who are still jaundiced at two weeks of age have benign causes (breastfeeding, breast milk, or hemolytic jaundice), a few will have biliary atresia or other diseases that require prompt diagnosis and treatment to optimize outcomes. Initiating evaluation at the two-week visit is important because some of these infants may not have another health care visit until they are two months old. (See  <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1">This approach results in screening between 60 and 375 healthy infants to detect one case of neonatal cholestasis [<a href="#rid3">3</a>]. To reduce the screening burden, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) suggests the following approach in jaundiced infants who are most likely to have breast milk jaundice because they are exclusively or near-exclusively breastfed: The evaluation for cholestasis may be delayed until three weeks of age in such infants if they have a normal physical examination, no history of dark urine or light stools, and can be reliably monitored [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other indications for evaluation include acholic (pale-colored stools) or conjugated hyperbilirubinemia (regardless of other signs or symptoms).</p><p></p><p class="headingAnchor" id="H12394983"><span class="h2">Total and conjugated bilirubin</span><span class="headingEndMark"> — </span>The first step in evaluating a jaundiced infant for possible cholestasis is to measure the serum concentrations of both total and conjugated bilirubin.</p><p class="bulletIndent1"><span class="glyph">●</span>If the infant has <strong>unconjugated</strong> hyperbilirubinemia (total bilirubin &gt;2 mg/dL [34.2 micromol/L] at two weeks of age with normal conjugated bilirubin), this is often caused by breast milk jaundice, but other causes also should be considered, particularly if the total bilirubin is markedly elevated. (See  <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/5947.html" rel="external">"Evaluation of jaundice caused by unconjugated hyperbilirubinemia in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the infant has <strong>conjugated </strong>hyperbilirubinemia, causes of cholestatic jaundice should be investigated promptly, as discussed in the remainder of this topic. Conjugated hyperbilirubinemia is defined as a serum conjugated bilirubin concentration greater than 1.0 mg/dL (17.1 micromol/L) irrespective of the total bilirubin concentration.</p><p></p><p class="bulletIndent1">In addition, infants with mildly elevated conjugated or direct bilirubin levels in the perinatal period (eg, &gt;0.3 or levels above the normal laboratory limit) should be followed closely with repeat laboratory measurements and further evaluation if the abnormality worsens [<a href="#rid7">7</a>]. However, routine screening of asymptomatic neonates for conjugated hyperbilirubinemia is not currently recommended. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Laboratory studies'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Subsequent stages of evaluation</span><span class="headingEndMark"> — </span>The evaluation of an infant with conjugated hyperbilirubinemia is complex because many disorders can present with neonatal cholestasis  (<a class="graphic graphic_table graphicRef64995" href="/z/d/graphic/64995.html" rel="external">table 1</a>), and distinguishing among these disorders is difficult because of the lack of specific diagnostic tests. However, relatively few diagnoses account for the majority of cases  (<a class="graphic graphic_table graphicRef79511" href="/z/d/graphic/79511.html" rel="external">table 2</a>) [<a href="#rid8">8</a>]. In term infants, the most common causes of neonatal cholestasis are biliary atresia (25 to 40 percent) and an array of rare genetic disorders (25 percent collectively) [<a href="#rid3">3</a>]. In <strong>premature</strong> infants, cholestasis more frequently results from total parenteral nutrition or sepsis. Measurement of total and conjugated bilirubin concentrations prior to initiation of total parenteral nutrition can help differentiate etiologies of neonatal cholestasis. The causes of neonatal cholestasis are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a> and  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia"</a>.)</p><p>Evaluation should be undertaken in a staged approach [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The initial step is rapid diagnosis and early initiation of therapy of treatable disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biliary atresia must be identified early and differentiated from other causes of neonatal cholestasis because early surgical intervention (ie, before two months of age) results in a better outcome. Important steps in making this diagnosis are performing ultrasonography and liver biopsy; if these studies suggest obstruction, we proceed to cholangiogram. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conditions such as sepsis, hypothyroidism, panhypopituitarism, and inborn errors of metabolism (eg, galactosemia, tyrosinemia) must be recognized and treated promptly to avoid significant progression of the illness. For infants in whom these disorders are excluded, consultation with a pediatric gastroenterologist is warranted [<a href="#rid3">3</a>]. (See <a class="local">'Laboratory studies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional testing is directed at the diagnosis of specific conditions, such as PI typing for alpha-1 antitrypsin deficiency and sweat and/or genetic testing for cystic fibrosis, and at potential complications of liver disease such as coagulopathy, hyperammonemia, and hypoglycemia.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">HISTORY</span><span class="headingEndMark"> — </span>A wide variety of disorders may cause neonatal cholestasis, as outlined in the table  (<a class="graphic graphic_table graphicRef64995" href="/z/d/graphic/64995.html" rel="external">table 1</a>) and detailed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p>Aspects of the history that may be helpful in narrowing the differential diagnosis are summarized in the table  (<a class="graphic graphic_table graphicRef111411" href="/z/d/graphic/111411.html" rel="external">table 3</a>) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PHYSICAL EXAMINATION</span><span class="headingEndMark"> — </span>Specific components of the physical examination may be useful in narrowing the differential diagnosis and are outlined in the table  (<a class="graphic graphic_table graphicRef111410" href="/z/d/graphic/111410.html" rel="external">table 4</a>). Key features include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infants with biliary atresia are generally well-appearing, except for jaundice, and stools are often acholic (examples of <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.perinatalservicesbc.ca%2FDocuments%2FScreening%2FBiliaryAtresia%2FBA_Stool_Card_Print_2023Jan.pdf&amp;token=uFcJZ7Q%2FSiXmF52IeItihvky7gMdROgokJHsI%2Bo873jHV7pzWaPFG0rjlZV7fCUQcKNkSooTKqTzxwXlaqmiVz0HSmawo%2BxnpeejavtEimZr75tll%2FnscGrIsr6KHGT%2FjFF8FGmw3TB%2FLL5kqUSAaQ%3D%3D&amp;TOPIC_ID=5941" target="_blank">stool colors here</a>). Infants who present late (&gt;90 days of age) with biliary atresia may have features of advanced liver disease including failure to thrive, ascites, and hepatosplenomegaly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, infants who are ill-appearing or failing to thrive are more likely to have an infection or metabolic disease.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">LABORATORY STUDIES</span><span class="headingEndMark"> — </span>Laboratory studies can help assess the extent of hepatobiliary dysfunction and may identify an etiology. Staged laboratory evaluation is presented in the table  (<a class="graphic graphic_table graphicRef111409" href="/z/d/graphic/111409.html" rel="external">table 5</a>). These tests usually should be performed simultaneously with the imaging evaluation described below.</p><p class="headingAnchor" id="H2439322959"><span class="h2">Initial panel of tests</span><span class="headingEndMark"> — </span>The initial laboratory evaluation should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive metabolic panel:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total and conjugated bilirubin – To evaluate for conjugated hyperbilirubinemia (cholestasis) versus unconjugated hyperbilirubinemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) – To assess liver cell injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum alkaline phosphatase and gamma-glutamyl transpeptidase (GGTP) – These tests may provide supportive evidence for biliary obstruction. Furthermore, several genetic/metabolic disorders can be divided into high- and low-GGTP categories. For example, GGTP is typically elevated in biliary atresia and Alagille syndrome, while a normal to low GGTP is seen in most forms of progressive familial intrahepatic cholestasis, bile acid synthetic disorders, and arthrogryposis-renal dysfunction-cholestasis syndrome. (See  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total protein and albumin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The comprehensive metabolic panel includes electrolytes, bicarbonate, and glucose, as an initial screen for metabolic disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) – To further evaluate hepatocellular function and/or vitamin K deficiency.</p><p></p><p class="headingAnchor" id="H785160393"><span class="h2">Other laboratory tests</span><span class="headingEndMark"> — </span>Additional tests may be appropriate to evaluate for systemic illness or specific causes of liver disease. Selection of these tests will vary based on the clinical presentation  (<a class="graphic graphic_table graphicRef111409" href="/z/d/graphic/111409.html" rel="external">table 5</a>).</p><p>If genetic testing targeting neonatal cholestatic disorders is readily available, it should be considered early in the evaluation of neonatal cholestasis while simultaneously evaluating for biliary atresia and other treatable causes of neonatal cholestasis. Monogenic defects cause neonatal cholestasis in 25 to 50 percent of cases, and some (eg, Alagille syndrome, progressive familial intrahepatic cholestasis type 3, neonatal sclerosing cholangitis, cystic fibrosis) can present with features of biliary obstruction on liver biopsy pathology that can be difficult to distinguish from biliary atresia. Early identification of a genetic cause guides medical therapy and, sometimes, informs decisions about referral for liver transplant [<a href="#rid10">10</a>]. In one study in which genetic testing was performed on infants after excluding biliary atresia, the diagnostic yield was 60 percent [<a href="#rid11">11</a>]. Available next-generation sequencing techniques include targeted gene panels, whole-exome sequencing, and whole-genome sequencing [<a href="#rid12">12</a>]. Interpreting the results can be challenging because the implications of heterozygous variants may be unclear, knowledge about genotype-phenotype associations continues to evolve, and sequencing methods do not identify all types of genetic variation [<a href="#rid13">13</a>]. If genetic testing is undertaken, partnering with geneticists to aid in interpretation of results is recommended.</p><p>Matrix metalloproteinase-7 (MMP-7), a protease responsible for tissue remodeling, has been associated with liver fibrosis in biliary atresia. Multiple studies have shown that serum levels of MMP-7 are higher in cholestatic infants with biliary atresia compared with other causes of neonatal cholestasis, but further studies are needed before this test can be incorporated into a diagnostic algorithm. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Laboratory testing'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">IMAGING STUDIES</span><span class="headingEndMark"> — </span>Several imaging studies can assist in establishing the cause of the neonatal cholestasis. Most patients should be evaluated with abdominal ultrasonography. Hepatobiliary scintigraphy may be of use in some cases. It is important to complete these studies expeditiously since outcomes after Kasai portoenterostomy are improved with earlier intervention. Many patients will also require liver biopsy to establish the diagnosis. (See <a class="local">'Additional tests'</a> below and  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Ultrasonography</span><span class="headingEndMark"> — </span>We suggest abdominal ultrasonography as the initial test because it is noninvasive, easily available, and can identify structural abnormalities of the hepatobiliary tract and abdominal organs [<a href="#rid3">3</a>]. The main utility of this test is to exclude other anatomic causes of cholestasis (ie, choledochal cyst). However, certain findings may suggest the diagnosis of biliary atresia, including absent (or nonvisualized) gallbladder and the presence of the triangular cord sign (triangular or band-like periportal echogenic density &gt;3 mm in thickness) [<a href="#rid14">14,15</a>]. Ultrasound may also identify situs abnormalities, polysplenia, or vascular anomalies that could be associated with biliary atresia.</p><p class="headingAnchor" id="H2862160997"><span class="h2">Transient elastography</span><span class="headingEndMark"> — </span>In one study, transient elastography revealed greater liver stiffness in cholestatic infants with biliary atresia compared with those without [<a href="#rid16">16</a>]. Thus, elevated liver stiffness measurement provides some support for a diagnosis of biliary atresia and expedites evaluation. While these initial results are promising, further research is needed before this technique is routinely included in the evaluation of neonatal cholestasis.</p><p class="headingAnchor" id="H10"><span class="h2">Scintigraphy</span><span class="headingEndMark"> — </span>Hepatobiliary scintigraphy (sometimes known as a "HIDA scan") is an optional second step performed at institutions where this test is readily available, provided that it does not delay subsequent diagnostic steps. It may provide useful information about biliary obstruction. However, the test is associated with substantial numbers of false-positive results and occasional false-negative results (ie, excretion of tracer into the bowel despite biliary atresia) [<a href="#rid3">3,17</a>]. As a result, scintigraphy should be used only for supportive information and not to independently confirm or exclude the diagnosis of biliary atresia.</p><p>The test is performed by administering a technetium-labeled iminodiacetic acid analog intravenously and monitoring uptake by the liver and subsequent excretion into the biliary tree and intestine. Infants with biliary atresia usually have normal uptake of the isotope but absent excretion into the bile and intestine, whereas those with neonatal hepatitis typically have delayed uptake but appropriate excretion [<a href="#rid9">9</a>]. Thus, if scintigraphy demonstrates patency of the biliary tract, biliary atresia is unlikely, except in very young infants [<a href="#rid3">3</a>]. However, nonvisualization of the gallbladder or lack of excretion can occur in patients without biliary atresia [<a href="#rid18">18</a>]. The test depends upon adequate hepatocellular function, and pretreatment for five days with <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">phenobarbital</a> (5 mg/kg per day) increases the accuracy of this test by enhancing isotope excretion [<a href="#rid19">19</a>]. However, in most cases, we do not use phenobarbital, because it will delay diagnosis and does not obviate the need for liver biopsy. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Hepatobiliary scintigraphy'</a>.)</p><p>The sensitivity of scintigraphy in detecting biliary obstruction is approximately 99 percent, and the specificity ranges from 69 to 72 percent [<a href="#rid20">20</a>]. This range reflects variations in use by different centers [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4210891680"><span class="h2">Magnetic resonance cholangiopancreatography</span><span class="headingEndMark"> — </span>Magnetic resonance cholangiopancreatography (MRCP) has limited usefulness in the evaluation of neonatal cholestasis [<a href="#rid21">21</a>]. If it is performed, lack of visualization of the cystic duct or common hepatic duct supports a diagnosis of biliary atresia [<a href="#rid22">22</a>]. However, MRCP is not reliable for making the diagnosis, because the normal biliary tract is not consistently visualized in infants under three months of age, which leads to false-negative results. Moreover, young infants would likely require general anesthesia to perform this test.</p><p class="headingAnchor" id="H13"><span class="h1">ADDITIONAL TESTS</span></p><p class="headingAnchor" id="H2616402644"><span class="h2">Liver biopsy</span><span class="headingEndMark"> — </span>If the initial laboratory evaluation and imaging does not identify a specific diagnosis, we recommend performing a percutaneous liver biopsy, particularly when there is a clinical suspicion of biliary atresia or other causes of biliary tract obstruction [<a href="#rid3">3</a>]. The results can help to support the diagnosis of biliary atresia before moving on to an open cholangiogram, or help to differentiate this disorder from intrahepatic causes of cholestasis that might not require surgical exploration [<a href="#rid3">3,23</a>]. The biopsy should be interpreted by a pathologist with expertise in pediatric liver disease. If the results are equivocal and biopsy was performed when the infant was &lt;6 weeks of age, repeat biopsy may be necessary. (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Liver biopsy'</a>.)</p><p class="headingAnchor" id="H2237521"><span class="h2">Cholangiogram</span></p><p class="headingAnchor" id="H2238170"><span class="h3">Open cholangiogram</span><span class="headingEndMark"> — </span>If the above steps in the evaluation support the diagnosis of biliary atresia, the infant should be taken to the operating room. The first step is an intraoperative cholangiogram, which is the gold standard in the diagnosis of biliary atresia. If the intraoperative cholangiogram demonstrates biliary obstruction (ie, if the contrast does not fill the biliary tree or reach the intestine), the surgeon should perform a hepatoportoenterostomy (Kasai procedure). (See  <a class="medical medical_review" href="/z/d/html/14369.html" rel="external">"Biliary atresia", section on 'Cholangiogram'</a>.)</p><p class="headingAnchor" id="H2237786"><span class="h3">Endoscopic retrograde cholangiopancreatography</span><span class="headingEndMark"> — </span>Endoscopic retrograde cholangiopancreatography (ERCP) is an alternative technique available at a few select tertiary care centers [<a href="#rid3">3</a>]. It involves endoscopic intubation of the biliary and pancreatic ducts through the ampulla of Vater with a small catheter and injection of contrast material to facilitate radiologic visualization of the ductal systems. (See  <a class="medical medical_review" href="/z/d/html/5867.html" rel="external">"Endoscopic retrograde cholangiopancreatography (ERCP) for biliary disease in children"</a>.)</p><p>ERCP appears to be a sensitive and specific means of detecting biliary obstruction [<a href="#rid3">3,24-29</a>]. However, its utility in neonates is limited by the availability of appropriately-sized endoscopes [<a href="#rid29">29</a>], the need for deep sedation or general anesthesia in most cases [<a href="#rid3">3</a>], and the lack of validation. In select circumstances, ERCP can clarify the etiology of neonatal cholestasis (eg, identify a biliary cyst  (<a class="graphic graphic_diagnosticimage graphicRef62324" href="/z/d/graphic/62324.html" rel="external">image 1</a>)) and avoid the need for laparotomy.</p><p class="headingAnchor" id="H2921969023"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116507.html" rel="external">"Society guideline links: Pediatric liver disease"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116513.html" rel="external">"Society guideline links: Neonatal jaundice"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for evaluation</strong> – Any infant who is noted to be jaundiced at two weeks of age should be evaluated for cholestasis by measuring total serum bilirubin and conjugated (or direct) bilirubin. The laboratory evaluation of breastfed infants who have a normal physical examination, have normally colored stools and urine, and can be closely monitored may be delayed until they are three weeks of age. (See <a class="local">'Indications for evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial screening</strong> – In a young infant, a reasonable threshold for initiating a clinical evaluation is conjugated (or direct) bilirubin &gt;1.0 mg/dL (17.1 micromol/L). During the neonatal period, milder elevation of conjugated bilirubin is abnormal and warrants close follow-up. (See <a class="local">'Definitions'</a> above and <a class="local">'Total and conjugated bilirubin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Causes of cholestasis in neonates and young infants include several types of biliary obstruction, hepatic or systemic infection, metabolic diseases, and toxic or alloimmune insults  (<a class="graphic graphic_table graphicRef64995" href="/z/d/graphic/64995.html" rel="external">table 1</a>). Biliary atresia and neonatal hepatitis account for most cases of cholestasis in term infants. In premature infants, cholestasis more frequently results from total parenteral nutrition or sepsis. (See <a class="local">'Subsequent stages of evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of cholestatic jaundice in infants after two weeks of age should be undertaken in a staged approach, guided by a focused history  (<a class="graphic graphic_table graphicRef111411" href="/z/d/graphic/111411.html" rel="external">table 3</a>), physical examination  (<a class="graphic graphic_table graphicRef111410" href="/z/d/graphic/111410.html" rel="external">table 4</a>), and laboratory evaluation  (<a class="graphic graphic_table graphicRef111409" href="/z/d/graphic/111409.html" rel="external">table 5</a>). (See <a class="local">'Subsequent stages of evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The initial step is rapid diagnosis and early initiation of therapy of treatable disorders (eg, sepsis, hypothyroidism, inborn errors of metabolism). If genetic testing targeting neonatal cholestatic disorders is readily available, it should be considered early in the evaluation of neonatal cholestasis while simultaneously proceeding with the remainder of the workup. (See <a class="local">'Laboratory studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The next step is to distinguish biliary atresia from other causes of neonatal cholestasis because early surgical intervention for biliary atresia before 60 days of age results in improved outcomes. Key steps are ultrasonography and liver biopsy. (See <a class="local">'Imaging studies'</a> above and <a class="local">'Liver biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatobiliary scintigraphy provides supportive information about biliary obstruction and can be performed if the test is readily available and does not delay subsequent diagnostic steps. However, the test is associated with substantial numbers of both false-positive and false-negative results, so it should not be used solely to either confirm or exclude the diagnosis of biliary atresia. (See <a class="local">'Scintigraphy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional tests</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional testing is directed at the diagnosis of specific conditions and evaluation of associated complications (eg, coagulopathy). If jaundice fails to resolve in an infant in whom a treatable condition is diagnosed (eg, urinary tract infection or galactosemia) and treated, further evaluation should be performed. Selection of these tests depends upon the clinical presentation  (<a class="graphic graphic_table graphicRef111409" href="/z/d/graphic/111409.html" rel="external">table 5</a>). (See <a class="local">'Other laboratory tests'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopic retrograde cholangiopancreatography (ERCP) is not routinely recommended. However, if expertise in neonatal ERCP is available, this procedure can be used to detect extrahepatic obstruction, including biliary atresia or cholelithiasis. (See <a class="local">'Endoscopic retrograde cholangiopancreatography'</a> above.)</p><p></p><p class="headingAnchor" id="H1488783728"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert J Shulman, MD, Stephanie H Abrams, MD, MS, and Jessi Erlichman, MPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dick MC, Mowat AP. Hepatitis syndrome in infancy--an epidemiological survey with 10 year follow up. Arch Dis Child 1985; 60:512.</a></li><li><a class="nounderline abstract_t">Balistreri WF. Neonatal cholestasis. J Pediatr 1985; 106:171.</a></li><li><a class="nounderline abstract_t">Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64:154.</a></li><li><a class="nounderline abstract_t">Davis AR, Rosenthal P, Escobar GJ, Newman TB. Interpreting conjugated bilirubin levels in newborns. J Pediatr 2011; 158:562.</a></li><li><a class="nounderline abstract_t">Winfield CR, MacFaul R. Clinical study of prolonged jaundice in breast- and bottle-fed babies. Arch Dis Child 1978; 53:506.</a></li><li><a class="nounderline abstract_t">Kelly DA, Stanton A. Jaundice in babies: implications for community screening for biliary atresia. BMJ 1995; 310:1172.</a></li><li><a class="nounderline abstract_t">Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic Yield of Newborn Screening for Biliary Atresia Using Direct or Conjugated Bilirubin Measurements. JAMA 2020; 323:1141.</a></li><li><a class="nounderline abstract_t">el-Youssef M, Whitington PF. Diagnostic approach to the child with hepatobiliary disease. Semin Liver Dis 1998; 18:195.</a></li><li class="breakAll">McLin VA, Balistereri WF. Approach to neoonatal cholestasis. In: Pediatric Gastrointestinal Disease: Pathopsychology, Diagnosis, Management, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, 2004. p.1079.</li><li><a class="nounderline abstract_t">Ibrahim SH, Kamath BM, Loomes KM, Karpen SJ. Cholestatic liver diseases of genetic etiology: Advances and controversies. Hepatology 2022; 75:1627.</a></li><li><a class="nounderline abstract_t">Nicastro E, Di Giorgio A, Marchetti D, et al. Diagnostic Yield of an Algorithm for Neonatal and Infantile Cholestasis Integrating Next-Generation Sequencing. J Pediatr 2019; 211:54.</a></li><li><a class="nounderline abstract_t">Feldman AG, Sokol RJ. Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention. Neoreviews 2021; 22:e819.</a></li><li><a class="nounderline abstract_t">Jeyaraj R, Bounford KM, Ruth N, et al. The Genetics of Inherited Cholestatic Disorders in Neonates and Infants: Evolving Challenges. Genes (Basel) 2021; 12.</a></li><li><a class="nounderline abstract_t">Kanegawa K, Akasaka Y, Kitamura E, et al. Sonographic diagnosis of biliary atresia in pediatric patients using the "triangular cord" sign versus gallbladder length and contraction. AJR Am J Roentgenol 2003; 181:1387.</a></li><li><a class="nounderline abstract_t">Tan Kendrick AP, Phua KB, Ooi BC, et al. Making the diagnosis of biliary atresia using the triangular cord sign and gallbladder length. Pediatr Radiol 2000; 30:69.</a></li><li><a class="nounderline abstract_t">Wu JF, Lee CS, Lin WH, et al. Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy. Hepatology 2018; 68:616.</a></li><li><a class="nounderline abstract_t">Adeyemi A, States L, Wann L, et al. Biliary Excretion Noted on Hepatobiliary Iminodiacetic Acid Scan Does Not Exclude Diagnosis of Biliary Atresia. J Pediatr 2020; 220:245.</a></li><li><a class="nounderline abstract_t">Lee CH, Wang PW, Lee TT, et al. The significance of functioning gallbladder visualization on hepatobiliary scintigraphy in infants with persistent jaundice. J Nucl Med 2000; 41:1209.</a></li><li><a class="nounderline abstract_t">Majd M, Reba RC, Altman RP. Hepatobiliary scintigraphy with 99mTc-PIPIDA in the evaluation of neonatal jaundice. Pediatrics 1981; 67:140.</a></li><li><a class="nounderline abstract_t">Kianifar HR, Tehranian S, Shojaei P, et al. Accuracy of hepatobiliary scintigraphy for differentiation of neonatal hepatitis from biliary atresia: systematic review and meta-analysis of the literature. Pediatr Radiol 2013; 43:905.</a></li><li><a class="nounderline abstract_t">Ranucci G, Della Corte C, Alberti D, et al. Diagnostic approach to neonatal and infantile cholestasis: A position paper by the SIGENP liver disease working group. Dig Liver Dis 2022; 54:40.</a></li><li><a class="nounderline abstract_t">Dong C, Zhu HY, Chen YC, et al. Clinical Assessment of Differential Diagnostic Methods in Infants with Cholestasis due to Biliary Atresia or Non-Biliary Atresia. Curr Med Sci 2018; 38:137.</a></li><li><a class="nounderline abstract_t">Fox VL, Cohen MB, Whitington PF, Colletti RB. Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1996; 23:213.</a></li><li><a class="nounderline abstract_t">Iinuma Y, Narisawa R, Iwafuchi M, et al. The role of endoscopic retrograde cholangiopancreatography in infants with cholestasis. J Pediatr Surg 2000; 35:545.</a></li><li><a class="nounderline abstract_t">Derkx HH, Huibregtse K, Taminiau JA. The role of endoscopic retrograde cholangiopancreatography in cholestatic infants. Endoscopy 1994; 26:724.</a></li><li><a class="nounderline abstract_t">Wilkinson ML, Mieli-Vergani G, Ball C, et al. Endoscopic retrograde cholangiopancreatography in infantile cholestasis. Arch Dis Child 1991; 66:121.</a></li><li><a class="nounderline abstract_t">Shirai Z, Toriya H, Maeshiro K, Ikeda S. The usefulness of endoscopic retrograde cholangiopancreatography in infants and small children. Am J Gastroenterol 1993; 88:536.</a></li><li><a class="nounderline abstract_t">Guelrud M, Jaen D, Mendoza S, et al. ERCP in the diagnosis of extrahepatic biliary atresia. Gastrointest Endosc 1991; 37:522.</a></li><li><a class="nounderline abstract_t">Ohnuma N, Takahashi T, Tanabe M, et al. The role of ERCP in biliary atresia. Gastrointest Endosc 1997; 45:365.</a></li></ol></div><div id="topicVersionRevision">Topic 5941 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3874604" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hepatitis syndrome in infancy--an epidemiological survey with 10 year follow up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881579" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neonatal cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27429428" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074172" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interpreting conjugated bilirubin levels in newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686778" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical study of prolonged jaundice in breast- and bottle-fed babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7767152" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Jaundice in babies: implications for community screening for biliary atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32207797" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnostic Yield of Newborn Screening for Biliary Atresia Using Direct or Conjugated Bilirubin Measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773420" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnostic approach to the child with hepatobiliary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9773420" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnostic approach to the child with hepatobiliary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35229330" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cholestatic liver diseases of genetic etiology: Advances and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160058" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnostic Yield of an Algorithm for Neonatal and Infantile Cholestasis Integrating Next-Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850148" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34828443" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Genetics of Inherited Cholestatic Disorders in Neonates and Infants: Evolving Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14573442" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sonographic diagnosis of biliary atresia in pediatric patients using the "triangular cord" sign versus gallbladder length and contraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10663514" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Making the diagnosis of biliary atresia using the triangular cord sign and gallbladder length.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29486516" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32111380" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biliary Excretion Noted on Hepatobiliary Iminodiacetic Acid Scan Does Not Exclude Diagnosis of Biliary Atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914911" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The significance of functioning gallbladder visualization on hepatobiliary scintigraphy in infants with persistent jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787555" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepatobiliary scintigraphy with 99mTc-PIPIDA in the evaluation of neonatal jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519699" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Accuracy of hepatobiliary scintigraphy for differentiation of neonatal hepatitis from biliary atresia: systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34688573" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Diagnostic approach to neonatal and infantile cholestasis: A position paper by the SIGENP liver disease working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30074163" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical Assessment of Differential Diagnostic Methods in Infants with Cholestasis due to Biliary Atresia or Non-Biliary Atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8890068" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outpatient liver biopsy in children: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770378" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The role of endoscopic retrograde cholangiopancreatography in infants with cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7712965" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The role of endoscopic retrograde cholangiopancreatography in cholestatic infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994840" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endoscopic retrograde cholangiopancreatography in infantile cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8470635" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The usefulness of endoscopic retrograde cholangiopancreatography in infants and small children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1936828" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : ERCP in the diagnosis of extrahepatic biliary atresia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165316" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of ERCP in biliary atresia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
